London, 15 June 2015: Technavio, the independent tech-focused global research firm, has published a report on the global cancer vaccines market 2015-2019, which is expected to grow at a CAGR of 27.24% during the forecast period of 2014-2019.
Frequent occurrence of different types of cancer and the introduction of various cancer vaccines propel market growth in the global cancer vaccines market. Factors such as increasing number of people with cancer, rising public awareness of vaccines, presence of promising late-stage pipeline candidates, and vendors’ patient-assistance programs also augment growth in this market.
“Dendritic cells are cells taken from a patient’s immune system and treated with chemicals before being injected back into the patient. These cells produce an enhanced immune response against the malignant cells in the body and stimulate the other cells in the immune system to fight the cancerous cells,” says Faisal Ghaus, Vice President of Technavio.
“Physicians prefer a combination of cancer vaccines with pharmacotherapeutics to treat cancer. This not only increases the efficacy of the treatment but also helps improve the overall survival rate of patients.”
Key Market Drivers:
- Increase in Prevalence of Cancers.
- Strong Late-Stage Pipeline Vaccine Candidates.
- Increase in Awareness.
- Patient-Assistance Programs.
Key Market Trends:
- Strategic Alliances.
- Vaccines Used in Combination with Other Therapies.
- Growth in Emerging Markets.
Key Market Vendors:
- Dendreon Corp.
- GlaxoSmithKline plc
- Merck and Co. Inc.
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
